Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation

Chemistry and Biology

Volumn 15, Issue 10, 2008, Pages 1015-1022

  Dar, Arvin C ^a   Lopez, Michael S ^a   Shokat, Kevan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CHEMBIO; SIGNALING

Indexed keywords

DRUG; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE P60; PYRIMIDINE DERIVATIVE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; PROTEIN BINDING; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PIPERAZINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRIMIDINES;

EID: 53649083930     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.09.007     Document Type: Article

References (30)

1. Angell R.M., Angell T.D., Bamborough P., Bamford M.J., Chung C.W., Cockerill S.G., Flack S.S., Jones K.L., Laine D.I., Longstaff T., et al. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg. Med. Chem. Lett. 18 (2008) 4433-4437
2. Bishop A.C., Shah K., Liu Y., Witucki L., Kung C., and Shokat K.M. Design of allele-specific inhibitors to probe protein kinase signaling. Curr. Biol. 8 (1998) 257-266
3. Bishop A.C., Kung C.Y., Shah K., Witucki L., Shokat K.M., and Liu Y. Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach. J. Am. Chem. Soc. 121 (1999) 627-631
4. Blethrow J., Zhang C., Shokat K.M., and Weiss E.L. Design and use of analog-sensitive protein kinases. In: Ausubel F.M. (Ed). Current Protocols in Molecular Biology (2004), John Wiley & Sons, New York 1-19
5. Capdeville R., Buchdunger E., Zimmermann J., and Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1 (2002) 493-502
6. Cumming J.G., McKenzie C.L., Bowden S.G., Campbell D., Masters D.J., Breed J., and Jewsbury P.J. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 14 (2004) 5389-5394
7. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
8. Dimauro E.F., Newcomb J., Nunes J.J., Bemis J.E., Boucher C., Buchanan J.L., Buckner W.H., Cee V.J., Chai L., Deak H.L., et al. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: Synthesis, SAR, and in vivo anti-inflammatory activity. J. Med. Chem. 49 (2006) 5671-5686
9. Fersht A. Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding (1999), W.H. Freeman and Co., New York
10. Gill A.L., Frederickson M., Cleasby A., Woodhead S.J., Carr M.G., Woodhead A.J., Walker M.T., Congreve M.S., Devine L.A., Tisi D., et al. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48 (2005) 414-426
11. Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., Lippke J., and Saxena K. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13 (2004) 169-178
12. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., and Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271 (1996) 695-701
13. Heron N.M., Anderson M., Blowers D.P., Breed J., Eden J.M., Green S., Hill G.B., Johnson T., Jung F.H., McMiken H.H., et al. SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 1320-1323
14. Hubbard S.R., Wei L., Ellis L., and Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372 (1994) 746-754
15. Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M., Cole P.A., and Kuriyan J. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol. 4 (2006) e144 10.1371/journal.pbio.0040144 Published online May 2, 2006
16. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2 (2006) 358-364
17. Liu Y., Bishop A., Witucki L., Kraybill B., Shimizu E., Tsien J., Ubersax J., Blethrow J., Morgan D.O., and Shokat K.M. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 6 (1999) 671-678
18. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., and Wilson K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279 (2004) 31655-31663
19. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., and Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243
20. Okram B., Nagle A., Adrian F.J., Lee C., Ren P., Wang X., Sim T., Xie Y., Wang X., Xia G., et al. A general strategy for creating "inactive-conformation" abl inhibitors. Chem. Biol. 13 (2006) 779-786
21. Papa F.R., Zhang C., Shokat K., and Walter P. Bypassing a kinase activity with an ATP-competitive drug. Science 302 (2003) 1533-1537
22. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., and Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9 (2002) 268-272
23. Sawyers C.L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 1 (2002) 13-15
24. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., and Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3 (1999) 639-648
25. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
26. Seeliger M.A., Nagar B., Frank F., Cao X., Henderson M.N., and Kuriyan J. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure 15 (2007) 299-311
27. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
28. Vajpai N., Strauss A., Fendrich G., Cowan-Jacob S.W., Manley P.W., Grzesiek S., and Jahnke W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J. Biol. Chem. 283 (2008) 18292-18302
29. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
30. Xu W., Harrison S.C., and Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385 (1997) 595-602